Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Hepatocellular Carcinoma in Patients with Metabolic-Associated Fatty Liver Disease

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Estes et al Hepatol. 2018;67:123–133.
   PubMed Web of Science ®Google Scholar
• Samuel VT, Shulman GI. Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Ceramides. N Engl J Med. 2019;381:1866–1869.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: a Meta-analysis. Diabetes Care. 2018;41:372–382.
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–209.
   PubMed Web of Science ®Google Scholar
• Koh YX, Tan HJ, Liew YX, et al. Liver resection for nonalcoholic fatty liver disease-associated hepatocellular carcinoma. J Am Coll Surg. 2019;229:467–478.e1.
   PubMed Web of Science ®Google Scholar
• Cauchy F, Zalinski S, Dokmak S, et al. Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg. 2013;100:113–121.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of Liver Function in Patients with Hepatocellular Carcinoma: a New Evidence-Based Approach—The ALBI Grade. J Clin Oncol. 2015;33:550–558.
   PubMed Web of Science ®Google Scholar
• Yılmaz M, Kayançiçek H. A New Inflammatory Marker: elevated Monocyte to HDL Cholesterol Ratio Associated with Smoking. J Clin Med. 2018;7:76.
   PubMed Web of Science ®Google Scholar
• Kanbay M, Solak Y, Unal HU, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol. 2014;46:1619–1625.
   PubMed Web of Science ®Google Scholar
• Wei X, Chen F, Huang J, et al. Novel Risk Biomarker for Infective Endocarditis Patients with Normal Left Ventricular Ejection Fraction ― Monocyte to High-Density Lipoprotein Cholesterol Ratio. Circ J. 2018;82:283–288.
   Web of Science ®Google Scholar
• Stefan N, Häring H-U, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7:313–324.
   PubMed Web of Science ®Google Scholar
• Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18:599–612.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–380.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Osaki Y. Non-B, non-C hepatocellular carcinoma. Int J Oncol. 2013;43:1333–1342.
   PubMed Web of Science ®Google Scholar
• Li J, Liao Y, Suo L, et al. A novel prognostic index—neutrophil times γ-glutamyl transpeptidase to lymphocyte ratio (NγLR) predicts outcome for patients with hepatocellular carcinoma. Sci Rep. 2017;7:9229.
   PubMed Web of Science ®Google Scholar
• Zheng J, Seier K, Gonen M, et al. Utility of Serum Inflammatory Markers for Predicting Microvascular Invasion and Survival for Patients with Hepatocellular Carcinoma. Ann Surg Oncol. 2017;24:3706–3714.
   PubMed Web of Science ®Google Scholar
• Zhang W, Tan Y, Jiang L, et al. Prognostic nomogram for patients with non-B non-C hepatocellular carcinoma after curative liver resection. Int J Surg. 2017;44:160–165.
   PubMed Web of Science ®Google Scholar
• Le MH, Le DM, Baez TC, et al. Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023;S0168827823002192.
   Google Scholar
• Zhou J, Zhou F, Wang W, et al. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71:1851–1864.
   PubMed Web of Science ®Google Scholar
• Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes – from mechanisms to clinical trials. Metabolism. 2020;111:154299.
   Web of Science ®Google Scholar
• Ciardullo S, Monti T, Perseghin G. High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults with Type 2 Diabetes. Diabetes Care. 2021;44(2):519–525.
   PubMed Web of Science ®Google Scholar
• Lomonaco R, Godinez Leiva E, Bril F, et al. Advanced Liver Fibrosis Is Common in Patients with Type 2 Diabetes Followed in the Outpatient Setting: the Need for Systematic Screening. Diabetes Care. 2021;44(2):399–406.
   PubMed Web of Science ®Google Scholar
• Myers S, Neyroud-Caspar I, Spahr L, et al. NAFLD and MAFLD as emerging causes of HCC: a populational study. JHEP Rep. 2021;3:100231.
   PubMedGoogle Scholar
• Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155:1828–37. e2.
   PubMed Web of Science ®Google Scholar
• Kodama K, Kawaguchi T, Hyogo H, et al. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. J Gastroenterol Hepatol. 2019;34:1626–1632.
   PubMed Web of Science ®Google Scholar
• Lin YP, Wang PM, Chuang CH, et al. Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: a 10-Year Follow-Up Study. Front Oncol. 2022;12:816472.
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–80.
   PubMed Web of Science ®Google Scholar
• Liang W, Zhang L, Jiang G, et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. J Clin Oncol. 2015;33(8):861–869.
   PubMed Web of Science ®Google Scholar
• Lei Z, Li J, Wu D, et al. Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma Within the Milan Criteria. JAMA Surg. 2016;151(4):356–363.
   PubMed Web of Science ®Google Scholar
• Serenari M, Han KH, Ravaioli F, et al. A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. J Hepatol. 2020;73(4):855–862.
   PubMed Web of Science ®Google Scholar
• Wang Q, Qiao W, Zhang H, et al. Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma. Front Immunol. 2022;13:1019638.
   PubMed Web of Science ®Google Scholar
• Zhang ZM, Lai EC, Zhang C, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg. 2015;20:8–16.
   PubMed Web of Science ®Google Scholar
• Park SH, Kim BI, Yun JW, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol. 2004;19(6):694–698.
   PubMed Web of Science ®Google Scholar
• Oruc N, Ozutemiz O, Yuce G, et al. Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol. 2009;9:16.
   PubMed Web of Science ®Google Scholar
• Foroughi M, Maghsoudi Z, Khayyatzadeh S, Ghiasvand R, Askari G, Iraj B. Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver. Adv Biomed Res. 2016;5:28.
   PubMedGoogle Scholar
• Lee J, Yoon K, Ryu S, Chang Y, Kim H-R. High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men. PLoS One. 2017;12:e0172666.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li Z, Huang Z, et al. C-Reactive Protein Is an Indicator of the Immunosuppressive Microenvironment Fostered by Myeloid Cells in Hepatocellular Carcinoma. Front Oncol. 2022;11:774823.
   PubMed Web of Science ®Google Scholar
• Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. J Leukoc Biol. 2019;106(2):309–322.
   PubMed Web of Science ®Google Scholar
• Wen Y, Lambrecht J, Ju C, Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol. 2021;18(1):45–56.
   PubMed Web of Science ®Google Scholar
• Sung PS. Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma. Clin Mol Hepatol. 2022;28(3):333–350.
   PubMed Web of Science ®Google Scholar
• Crudele L, De Matteis C, Piccinin E, et al. Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis. JHEP Rep. 2022;5(1):100627.
   PubMedGoogle Scholar
• Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012;32(12):2813–2820.
   PubMed Web of Science ®Google Scholar
• Negi G, Kumar A, Joshi RP, Sharma SS. Oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: old perspective with a new angle. Biochem Biophys Res Commun. 2011;408(1):1–5.
   PubMed Web of Science ®Google Scholar
• Ganjali S, AM G, Ruscica M, et al. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases. J Cell Physiol. 2018;233(12):9237–9246.
   PubMed Web of Science ®Google Scholar
• Canpolat U, Cetin EH, Cetin S, et al. Association of Monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation. Clin Appl Thromb Hemost. 2016;22(5):476–482.
   PubMed Web of Science ®Google Scholar
• Acikgoz SK, Acikgoz E, Sensoy B, Topal S, Aydogdu S. Monocyte to High-Density Lipoprotein Cholesterol Ratio Is Predictive of in-Hospital and Five-Year Mortality in ST-Segment Elevation Myocardial Infarction. Cardiol J. 2016;23:505–12.
   PubMed Web of Science ®Google Scholar
• Chen SA, Zhang MM, Zheng M, et al. The Preablation Monocyte/ High Density Lipoprotein Ratio Predicts the Late Recurrence of Paroxysmal Atrial Fibrillation After Radiofrequency Ablation. BMC Cardiovasc Disord. 2020;20:401.
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and Cancer: triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27–41.
   PubMed Web of Science ®Google Scholar
• Yu X, Mi S, Ye J, Lou G. Aberrant lipid metabolism in cancer cells and tumor microenvironment: the player rather than bystander in cancer progression and metastasis. J Cancer. 2021;12(24):7498–7506.
   PubMed Web of Science ®Google Scholar
• Long J, Zhang CJ, Zhu N, et al. Lipid metabolism and carcinogenesis, cancer development. Am J Cancer Res. 2018;8(5):778–791.
   PubMed Web of Science ®Google Scholar
• Paul B, Lewinska M, Andersen JB. Lipid alterations in chronic liver disease and liver cancer. JHEP Rep. 2022;4(6):100479.
   PubMedGoogle Scholar